Besilesomab

A radiolabeled antibody used as an imaging agent to detect sites of infection or inflammation, particularly osteomyelitis and infected prosthetic implants. It works by binding to white blood cells recruited to infected areas, which are then visualized using nuclear imaging. Its use is limited by regulatory approval status in different regions.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Besilesomab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.